Inhibition of Yes-Associated Protein by Verteporfin Ameliorates Unilateral Ureteral Obstruction-Induced Renal Tubulointerstitial Inflammation and Fibrosis
Open accessThe DOI matches its Crossref record; 44 of the 44 references it cites were found in a registry or an index.
Abstract
Yes-associated protein (YAP) activation after acute ischemic kidney injury might be related to interstitial fibrosis and impaired renal tubular regeneration. Verteporfin (VP) is a photosensitizer used in photodynamic therapy to treat age-related macular degeneration. In cancer cells, VP inhibits TEA domain family member (TEAD)-YAP interactions without light stimulation. The protective role of VP in unilateral ureteral obstruction (UUO)-induced renal fibrosis and related mechanisms remains unclear. In this study, we investigate the protective effects of VP on UUO-induced renal tubulointerstitial inflammation and fibrosis and its regulation of the transforming growth factor-β1 (TGF-β1)/Smad signaling pathway. We find that VP decreased the UUO-induced increase in tubular injury, inflammation, and extracellular matrix deposition in mice. VP also decreased myofibroblast activation and proliferation in UUO kidneys and NRK-49F cells by modulating Smad2 and Smad3 phosphorylation. Therefore, YAP inhibition might have beneficial effects on UUO-induced tubulointerstitial inflammation and fibrosis by regulating the TGF-β1/Smad signaling pathway.
Overview
Integrity signals
Registry
Cites
Statistics
Figures






Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Verteporfin, a direct inhibitor of YAP-TEAD binding and transcriptional activity, significantly reduced collagen I and fibronectin expression and ameliorated fibrosis severity in a unilateral ureteral obstruction (UUO) kidney fibrosis model, while improving epithelial structural integrity (146, 147).”
From The mechanotransduction-immune axis in organ fibrosis: dual regulatory mechanisms and translational therapeutic perspectives (2025) · doi:10.3389/fimmu.2025.1670213 · cites this paper as [147]
Citations
Cites
Wang, H., Naghavi, M., Allen, C., Barber, R. M., Bhutta, Z. A., Carter, A., Casey, D. C., Charlson, F. J., Chen, A. Z., Coates, M. M., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)31012-1 · Cited by 6,596
Mechanisms of fibrosis: therapeutic translation for fibrotic disease
Wynn, T. A., & Ramalingam, T. R. (2012) · Nature Medicine · doi:10.1038/nm.2807 · Cited by 3,541 · cited 1×
“The infiltration of polymorphonuclear neutrophils and monocytes is characteristic of the initial inflammatory response to injury [28,29].”
BackgroundTGF-β: the master regulator of fibrosis
Meng, X.-M., Nikolic-Paterson, D. J., & Lan, H. Y. (2016) · Nature Reviews Nephrology · doi:10.1038/nrneph.2016.48 · Cited by 3,528
Resolving inflammation: dual anti-inflammatory and pro-resolution lipid mediators
Serhan, C. N., Chiang, N., & Van Dyke, T. E. (2008) · Nature Reviews Immunology · doi:10.1038/nri2294 · Cited by 2,932 · cited 1×
“The infiltration of polymorphonuclear neutrophils and monocytes is characteristic of the initial inflammatory response to injury [28,29].”
BackgroundThe Biology of YAP/TAZ: Hippo Signaling and Beyond
Piccolo, S., Dupont, S., & Cordenonsi, M. (2014) · Physiological Reviews · doi:10.1152/physrev.00005.2014 · Cited by 1,802 · cited 2×
“YAP is related to nephron morphogenesis, and TAZ inactivation causes polycystic kidney disease [14].”
BackgroundMechanisms of Hippo pathway regulation
Meng, Z., Moroishi, T., & Guan, K.-L. (2016) · Genes & Development · doi:10.1101/gad.274027.115 · Cited by 1,667 · cited 12×
“Once the Hippo pathway has been activated, it limits tissue growth and cell proliferation through the phosphorylation and degradation of YAP/TAZ.”
BackgroundInfluentialLiu-Chittenden, Y., Huang, B., Shim, J. S., Chen, Q., Lee, S.-J., Anders, R. A., Liu, J. O., & Pan, D. (2012) · Genes & Development · doi:10.1101/gad.192856.112 · Cited by 1,452 · cited 1×
“showed that VP inhibits TEA domain family member (TEAD)–YAP interactions in cancer cells without light stimulation [16].”
BackgroundThe Hippo Pathway: Biology and Pathophysiology
Ma, S., Meng, Z., Chen, R., & Guan, K.-L. (2019) · Annual Review of Biochemistry · doi:10.1146/annurev-biochem-013118-111829 · Cited by 1,387 · cited 2×
“In contrast, when the Hippo pathway is turned off, YAP/TAZ is dephosphorylated and translocated into the nucleus to induce target gene transcription [12,13].”
BackgroundThe Hippo–YAP pathway in organ size control and tumorigenesis: an updated version
Zhao, B., Li, L., Lei, Q., & Guan, K.-L. (2010) · Genes & Development · doi:10.1101/gad.1909210 · Cited by 1,144
Chapter 1: Definition and classification of CKD
(2013) · Kidney International Supplements · doi:10.1038/kisup.2012.64 · Cited by 1,110
Mechanosignaling through YAP and TAZ drives fibroblast activation and fibrosis
Liu, F., Lagares, D., Choi, K. M., Stopfer, L., Marinković, A., Vrbanac, V., Probst, C. K., Hiemer, S. E., Sisson, T. H., Horowitz, J. C., et al. (2015) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00300.2014 · Cited by 874
Connective tissue growth factor: a mediator of TGF-β action on fibroblasts
Grotendorst, G. R. (1997) · Cytokine & Growth Factor Reviews · doi:10.1016/s1359-6101(97)00010-5 · Cited by 761
Kanai, F., Marignani, P. A., Sarbassova, D., Yagi, R., Hall, R. A., Donowitz, M., Hisaminato, A., Fujiwara, T., Ito, Y., Cantley, L. C., et al. (2000) · The EMBO Journal · doi:10.1093/emboj/19.24.6778 · Cited by 756
Extracellular matrix as a driver of progressive fibrosis
Herrera, J., Henke, C. A., & Bitterman, P. B. (2018) · Journal of Clinical Investigation · doi:10.1172/jci93557 · Cited by 615 · cited 1×
“The excessive accumulation of ECM protein drives progressive organ fibrosis, which increases tissue stiffness and activates the mechanosensitive Hippo pathway effector YAP [25].”
BackgroundRenal fibrosis: novel insights into mechanisms and therapeutic targets
Boor, P., Ostendorf, T., & Floege, J. (2010) · Nature Reviews Nephrology · doi:10.1038/nrneph.2010.120 · Cited by 606 · cited 1×
“After an ischemic or toxic injury to the kidneys causes damage to glomerular, vascular, and tubular cells, an inflammatory reaction can increase the deposition of the extracellular matrix (ECM) in the renal parenchyma [7].”
BackgroundA WW domain-containing Yes-associated protein (YAP) is a novel transcriptional co-activator
Yagi, R., Chen, L.-F., Shigesada, K., Murakami, Y., & Ito, Y. (1999) · The EMBO Journal · doi:10.1093/emboj/18.9.2551 · Cited by 558
YAP/TAZ Are Mechanoregulators of TGF-β-Smad Signaling and Renal Fibrogenesis
Szeto, S. G., Narimatsu, M., Lu, M., He, X., Sidiqi, A. M., Tolosa, M. F., Chan, L., De Freitas, K., Bialik, J. F., Majumder, S., et al. (2016) · Journal of the American Society of Nephrology · doi:10.1681/asn.2015050499 · Cited by 462 · cited 1×
“The Hippo pathway plays an essential role in kidney and urinary tract development [33,34], cystic kidney disease [35,36], podocyte integrity [37], diabetic nephropathy [31], renal cell carcinoma [38], and tubulointerstitial fibrosis [39].”
BackgroundSignaling in Fibrosis: TGF-β, WNT, and YAP/TAZ Converge
Piersma, B., Bank, R. A., & Boersema, M. (2015) · Frontiers in Medicine · doi:10.3389/fmed.2015.00059 · Cited by 442
Morin-Kensicki, E. M., Boone, B. N., Howell, M., Stonebraker, J. R., Teed, J., Alb, J. G., Magnuson, T. R., O'Neal, W., & Milgram, S. L. (2006) · Molecular and Cellular Biology · doi:10.1128/mcb.26.1.77-87.2006 · Cited by 429 · cited 1×
“The Hippo pathway plays an essential role in kidney and urinary tract development [33,34], cystic kidney disease [35,36], podocyte integrity [37], diabetic nephropathy [31], renal cell carcinoma [38], and tubulointerstitial fibrosis [39].”
BackgroundLifetime Incidence of CKD Stages 3-5 in the United States
Grams, M. E., Chow, E. K. H., Segev, D. L., & Coresh, J. (2013) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2013.03.009 · Cited by 302 · cited 2×
“As human life expectancy has increased, CKD has become one of the most common non-communicable diseases [2,3].”
BackgroundGlomerulocystic kidney disease in mice with a targeted inactivation of Wwtr1
Hossain, Z., Ali, S. M., Ko, H. L., Xu, J., Ng, C. P., Guo, K., Qi, Z., Ponniah, S., Hong, W., & Hunziker, W. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0605266104 · Cited by 297 · cited 1×
“The Hippo pathway plays an essential role in kidney and urinary tract development [33,34], cystic kidney disease [35,36], podocyte integrity [37], diabetic nephropathy [31], renal cell carcinoma [38], and tubulointerstitial fibrosis [39].”
BackgroundTGF-β signaling in the kidney: profibrotic and protective effects
Sureshbabu, A., Muhsin, S. A., & Choi, M. E. (2016) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00365.2015 · Cited by 267 · cited 3×
“is a multifunctional cytokine related to cell growth, differentiation, apoptosis, and wound repair [8].”
BackgroundFibroblast activation and myofibroblast generation in obstructive nephropathy
Grande, M. T., & López-Novoa, J. M. (2009) · Nature Reviews Nephrology · doi:10.1038/nrneph.2009.74 · Cited by 265 · cited 1×
“The loss of the glomerular and peritubular capillary architecture, the proliferation of tubular cells and interstitial fibroblasts, the increases in proinflammatory cytokines and chemokines, the infiltration of inflammatory cells, and the diffuse accumulation of ECM are common histologic features in renal fibrosis [24…”
BackgroundNon-canonical (non-SMAD2/3) TGF-β signaling in fibrosis: Mechanisms and targets
Finnson, K. W., Almadani, Y., & Philip, A. (2020) · Seminars in Cell & Developmental Biology · doi:10.1016/j.semcdb.2019.11.013 · Cited by 179 · cited 1×
“TGF-β also activates other, non-canonical (Smad-independent) pathways, such as mitogen-activated protein kinase, phosphatidylinositol-3-kinase, and Rho-like GTPase [11].”
BackgroundConnective tissue growth factor (CCN2, CTGF) and organ fibrosis: lessons from transgenic animals
Brigstock, D. R. (2010) · Journal of Cell Communication and Signaling · doi:10.1007/s12079-009-0071-5 · Cited by 134 · cited 1×
“CTGF is a matricellular protein that has been associated with wound healing and organ fibrosis [22].”
BackgroundImpact of chronic kidney disease on mortality: A nationwide cohort study
Kim, K. M., Oh, H. J., Choi, H. Y., Lee, H., & Ryu, D. (2019) · Kidney Research and Clinical Practice · doi:10.23876/j.krcp.18.0128 · Cited by 127 · cited 10×
“Therefore, modulation of the TGF-β1 signaling pathway is an important therapeutic target for preventing progressive CKD.”
BackgroundInfluentialAltered Hippo signalling in polycystic kidney disease
Happé, H., van der Wal, A. M., Leonhard, W. N., Kunnen, S. J., Breuning, M. H., de Heer, E., & Peters, D. J. (2011) · The Journal of Pathology · doi:10.1002/path.2856 · Cited by 121 · cited 1×
“The Hippo pathway plays an essential role in kidney and urinary tract development [33,34], cystic kidney disease [35,36], podocyte integrity [37], diabetic nephropathy [31], renal cell carcinoma [38], and tubulointerstitial fibrosis [39].”
BackgroundInteraction of the EGF Receptor and the Hippo Pathway in the Diabetic Kidney
Chen, J., & Harris, R. C. (2016) · Journal of the American Society of Nephrology · doi:10.1681/asn.2015040415 · Cited by 119 · cited 2×
“In diabetic nephropathy, EGF receptor-dependent upregulation of YAP increases the levels of downstream profibrotic factors such as CTGF and amphiregulin [31].”
BackgroundPodocyte-Specific Deletion of Yes-Associated Protein Causes FSGS and Progressive Renal Failure
Schwartzman, M., Reginensi, A., Wong, J., Basgen, J. M., Meliambro, K. A., Nicholas, S. B., D’Agati, V. D., McNeill, H., & Campbell, K. N. (2015) · Journal of the American Society of Nephrology · doi:10.1681/asn.2014090916 · Cited by 118 · cited 2×
“Podocyte-specific Yap deletion results in proteinuria between 5 and 6 weeks of age and leads to focal segmental glomerular sclerosis at 12 weeks [37].”
BackgroundRaghunathan, V. K., Morgan, J. T., Dreier, B., Reilly, C. M., Thomasy, S. M., Wood, J. A., Ly, I., Tuyen, B. C., Hughbanks, M., Murphy, C. J., et al. (2013) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.12-11007 · Cited by 116 · cited 1×
“Notably, connective tissue growth factor (CTGF) and TGF-β, which regulate the extent of remodeling in the tissue architecture, are among the YAP transcription targets [17].”
BackgroundSahin, H., & Wasmuth, H. E. (2012) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2012.11.004 · Cited by 113 · cited 2×
“To initiate the wound healing process, the recruitment of inflammatory cells is a fundamental process [27].”
BackgroundKidney health for everyone everywhere—from prevention to detection and equitable access to care
Li, P. K.-T., Garcia-Garcia, G., Lui, S.-F., Andreoli, S., Fung, W. W.-S., Hradsky, A., Kumaraswami, L., Liakopoulos, V., Rakhimova, Z., Saadi, G., et al. (2020) · Kidney International · doi:10.1016/j.kint.2019.12.002 · Cited by 110
Schütte, U., Bisht, S., Heukamp, L. C., Kebschull, M., Florin, A., Haarmann, J., Hoffmann, P., Bendas, G., Buettner, R., Brossart, P., et al. (2014) · Translational Oncology · doi:10.1016/j.tranon.2014.02.005 · Cited by 102 · cited 1×
“The Hippo pathway plays an essential role in kidney and urinary tract development [33,34], cystic kidney disease [35,36], podocyte integrity [37], diabetic nephropathy [31], renal cell carcinoma [38], and tubulointerstitial fibrosis [39].”
BackgroundHippo and TGF-β interplay in the lung field
Saito, A., & Nagase, T. (2015) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00238.2015 · Cited by 91
Quan, Y., Park, W., Jin, J., Kim, W., Park, S. K., & Kang, K. P. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21020402 · Cited by 87 · cited 4×
“Renal fibrosis was induced using a UUO operation described previously [21].”
BackgroundMethodSelf-citationKim, D., Lee, A. S., Jung, Y. J., Yang, K. H., Lee, S., Park, S. K., Kim, W. B., & Kang, K. P. (2014) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfu240 · Cited by 85 · cited 3×
“Previously, we found that inhibiting the TGF/Smad signaling pathway by modulating estrogen receptor α and activating mitochondrial Sirt3 ameliorated UUO-induced renal inflammation and fibrosis [9,21].”
BackgroundSelf-citationDeregulation of Hippo–TAZ pathway during renal injury confers a fibrotic maladaptive phenotype
Anorga, S., Overstreet, J. M., Falke, L. L., Tang, J., Goldschmeding, R. G., Higgins, P. J., & Samarakoon, R. (2018) · The FASEB Journal · doi:10.1096/fj.201700722r · Cited by 85 · cited 1×
“TGF-β1-dependent TAZ activation promotes maladaptive epithelial repair through Smad3-dependent CTGF up-regulation [32].”
BackgroundHe, W., & Dai, C. (2015) · Current Pathobiology Reports · doi:10.1007/s40139-015-0077-z · Cited by 84 · cited 2×
“Organ fibrosis is characterized by a dynamic process of non-resolving inflammatory reactions [6] that cause the deterioration of organ function.”
BackgroundXu, J., Li, P.-X., Wu, J., Gao, Y.-J., Yin, M.-X., Lin, Y., Yang, M., Chen, D.-P., Sun, H.-P., Liu, Z.-B., et al. (2016) · Clinical Science · doi:10.1042/cs20150385 · Cited by 79 · cited 2×
“The constant activation of YAP after acute ischemic kidney injury might be related to interstitial fibrosis and impaired renal tubular regeneration [19].”
BackgroundHippo signaling in the kidney: the good and the bad
Wong, J. S., Meliambro, K., Ray, J., & Campbell, K. N. (2016) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00500.2015 · Cited by 67
A CTGF-YAP Regulatory Pathway Is Essential for Angiogenesis and Barriergenesis in the Retina
Moon, S., Lee, S., Caesar, J., Pruchenko, S., Leask, A., Knowles, J. A., Sinon, J., & Chaqour, B. (2020) · iScience · doi:10.1016/j.isci.2020.101184 · Cited by 65 · cited 1×
“Recently, YAP and CTGF were found to be closely involved in determining blood vessel integrity and stability in the retina [18].”
BackgroundYap and Taz are required for Ret-dependent urinary tract morphogenesis
Reginensi, A., Hoshi, M., Boualia, S. K., Bouchard, M., Jain, S. R., & McNeill, H. (2015) · Development · doi:10.1242/dev.122044 · Cited by 55
Chen, W., Cao, Z., Krishnan, C., & Panjwani, N. (2015) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2015.09.012 · Cited by 54 · cited 1×
“Verteporfin (VP) is a photosensitizer already used in photodynamic therapy to treat age-related macular degeneration [15].”
BackgroundNguyen, T. T., Kim, D., Lee, S., Kim, W. B., Park, S. M., & Kang, K. P. (2017) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2017.3218 · Cited by 46 · cited 3×
“The Western blot analysis was performed as described previously [20].”
BackgroundMethodSelf-citation
Cited by
The Hippo signalling pathway and its implications in human health and diseases
Fu, M., Hu, Y., Lan, T., Guan, K.-L., Luo, T., & Luo, M. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01191-9 · Cited by 742
Epithelial–mesenchymal transition in tissue repair and degeneration
Youssef, K. K., & Nieto, M. A. (2024) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-024-00733-z · Cited by 159
“Verteporfin, a drug that blocks the interaction between YAP/TAZ and their effector TEAD, reduces TGFβ–SMAD signalling, decreases inflammation and myofibroblast activation in a model of murine renal fibrosis 220 (Fig.”
YAP/TAZ: Molecular pathway and disease therapy
Wei, Y., Hui, V. L. Z., Chen, Y., Han, R., Han, X., & Guo, Y. (2023) · MedComm · doi:10.1002/mco2.340 · Cited by 122
Yeh, T.-H., Tu, K.-C., Wang, H., & Chen, J. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25031755 · Cited by 120
“…of 22 Another compound, Vertepor fi n (VP), a photosensitizer used in treating age-related macular degeneration, can bind to YAP, disrupting its interaction with TEAD, which might improve renal tubulointerstitial in fl ammation and fi brosis [139,140]. modulation of the Hippo signaling pathway [138].”
BackgroundDecellularized Disc Hydrogels for hBMSCs tissue-specific differentiation and tissue regeneration
Peng, Y., Qing, X., Lin, H., Huang, D., Li, J., Tian, S., Liu, S., Lv, X., Ma, K., Li, R., et al. (2021) · Bioactive Materials · doi:10.1016/j.bioactmat.2021.03.014 · Cited by 90
Metadata
- Authors
- Jin, J., Wang, T., Park, W., Li, W., Kim, W., Park, S. K., & Kang, K. P.
- Affiliations
- Jeonbuk National University Hospital (KR)
- Corresponding author
- Park, Sung Kwang
- Kang, Kyung Pyo
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2020-10-31
- Volume
- 21
- Issue
- 21
- Pages
- 8184
- ISSN
- 1422-0067 (ISSN-L)
- PMC
- PMC7662854
- OpenAlex
- W3095066918
- Cited by
- 43
- References
- 44
- Citations by year
- 2026: 7 · 2025: 7 · 2024: 7 · 2023: 8 · 2022: 8 · 2021: 5 · 2020: 1
- FWCI
- 2.74
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- International Journal of Molecular Sciences (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- Funders
- National Research Foundation of Korea (NRF-2018R1D1A1B07045790, NRF- 2017R1D1A3B03035494)
- Fund of Biomedical Research Institute, Jeonbuk National University Hospital (CUH2020-0014)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Hippo pathway signaling and YAP/TAZ
- Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › TGF-β signaling in diseases
- Keywords
- verteporfin, YAP, unilateral ureteral obstruction, tubulointerstitial fibrosis, tubulointerstitial inflammation, TGF-β1/Smad signaling, myofibroblast activation, extracellular matrix deposition, acute kidney injury, kidney regeneration
- MeSH terms
- Verteporfin, YAP-Signaling Proteins, Animals, Cells, Cultured, Disease Models, Animal, Fibrosis, Inflammation, Kidney Diseases, Male, Mice, Inbred C57BL, Ureteral Obstruction, Photosensitizing Agents, Cell Cycle Proteins, Adaptor Proteins, Signal Transducing, Mice, Rats
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.